ETF Channel: Analysts See 19% Upside for iShares US Pharmaceuticals ETF IHE
ByAinvest
Friday, Mar 20, 2026 8:53 am ET1min read
CRMD--
EOLS--
IHE--
RAPP--
Analysts see nearly 19% upside for the iShares US Pharmaceuticals ETF (IHE) based on the average analyst 12-month forward target price for its underlying holdings. Three holdings with notable upside to their analyst target prices are Evolus Inc, CorMedix Inc, and Rapport Therapeutics Inc, with potential gains of 220%, 129%, and 90%, respectively. IHE tracks the Dow Jones U.S. Select Pharmaceuticals Index and holds large and mid-cap drug manufacturers, with analysts expecting gains in chronic-disease treatments, specialty biologics, oncology, and neurology.

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet